Latest news with #Arrowhead
Yahoo
16 hours ago
- Sport
- Yahoo
FIFA World Cup 26 CEO discusses how Kansas City is preparing
KANSAS CITY, Mo. — The World Cup comes to Kansas City in less than a year. Perhaps the largest sporting event in the world, spread out over five weeks. Kansas City is one of 16 North American host cities, with Arrowhead set to host six matches. See the latest headlines in Kansas City and across Kansas, Missouri The region will also be a base camp for up to three teams. As the weeks fly by, how prepared is the city when it comes to transportation, security, volunteers, and more? This week, FOX4 sits down with FIFA World Cup 26 CEO Pam Kramer to get some answers. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
2 days ago
- Business
- Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'may,' 'will,' 'expect,' 'believe,' 'anticipate,' 'hope,' 'intend,' 'plan,' 'project,' 'could,' 'estimate,' 'continue,' 'target,' 'forecast' or 'continue' or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.
Yahoo
5 days ago
- Business
- Yahoo
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
Shares of Sarepta Therapeutics SRPT surged more than 30% in after-market trading yesterday after the company announced a strategic restructuring plan focused on pipeline reprioritization and supporting long-term financial sustainability. SRPT to Cut Costs & Focus on siRNA Pipeline Sarepta's restructuring plan aims to save about $400 million annually starting in 2026. To achieve this target, the company has decided to lay off 36% of its workforce — around 500 employees — which is expected to save nearly $120 million per year. SRPT plans to generate around $300 million in annual savings by reprioritizing its pipeline. Concerning the pipeline, Sarepta has decided to pause development of most of its gene-therapy candidates for limb-girdle muscular dystrophy (LGMD). The company, however, intends to move forward with SRP-9003, its gene therapy candidate for patients with LGMD type 2E/R4 (LGMD2E/R4, or beta sarcoglycanopathy). A regulatory filing with the FDA remains on track for this therapy before year-end. SRPT has now shifted focus to its siRNA programs, which were acquired as part of a multi-billion-dollar licensing deal with Arrowhead Pharmaceuticals ARWR. After closing the Arrowhead deal in February, Sarepta acquired exclusive rights to four clinical-stage siRNA programs, each being evaluated in separate phase I/II studies. These include SRP-1001 in facioscapulohumeral muscular dystrophy (FSHD), SRP-1002 in idiopathic pulmonary fibrosis (IPF), SRP-1003 in myotonic dystrophy type 1 (DM1) and SRP-1004 in spinocerebellar ataxia 2 (SCA2). Initial data from studies on SRP-1001 and SRP-1003 are expected before year-end. Sarepta also acquired three preclinical programs from Arrowhead, including SRP-1005 (for Huntington's disease), which is set to enter clinical development early next year. While Sarepta expects to incur severance and one-time charges of $32 million to $37 million, it still anticipates saving over $100 million in annual costs this year. For full-year 2026, Sarepta expects the combined adjusted R&D and SG&A expenses to be in the range of $800-$900 million. SRPT Stock Performance Sarepta's motivation behind these moves is clear — this company-wide reorganization aims to address the setback stemming from safety concerns around Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). The latest surge in stock price reflects investor optimism regarding the restructuring plan's ability to stabilize the company's financial profile and growth trajectory. Year to date, Sarepta's shares have plunged 85% compared with the industry's 2% decline. Image Source: Zacks Investment Research Sarepta to Update Elevidys Label With Black Box Warning Investor sentiment toward the stock has worsened significantly after two patient deaths were linked to Elevidys, both caused by acute liver failure (ALF) in non-ambulatory DMD patients. While Sarepta has already suspended both clinical and commercial Elevidys dosing for non-ambulatory patients, the therapy has been mandated by the FDA to carry a black box warning for ALF and acute liver injury. To address this safety issue, Sarepta is working to create a new protocol with an enhanced immunosuppression regimen to make Elevidys administration safer for non-ambulatory DMD patients. The company plans to submit these findings to the FDA in hopes of resuming dosing in the non-ambulation population. Sarepta developed Elevidys in partnership with pharma giant Roche RHHBY. In 2019, SRPT and Roche entered into a licensing agreement to develop Elevidys. Per the agreement, Roche has exclusive rights to launch and market the therapy in non-U.S. markets. Sarepta Provides Q2 Preliminary Numbers Alongside the restructuring plan, Sarepta also issued preliminary/unaudited figures for the second quarter of 2025. The company reported total net product revenues of $513 million, which beat both the Zacks Consensus Estimate of $506 million and our model estimate of $507 million. The unaudited revenue numbers include $282 million from Elevidys. The Zacks Consensus Estimate and our model estimate for Elevidys' sales are pegged at $274 million and $280 million, respectively. Sarepta also reported preliminary combined adjusted R&D and SG&A expenses of around $294 million for the quarter. As of the end of June 2025, unaudited cash and short-term investments totaled approximately $850 million. The company plans to report full second-quarter results early next month. Sarepta Therapeutics, Inc. Price Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote SRPT's Zacks Rank Sarepta currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
08-07-2025
- Business
- Business Wire
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran (licensed to Takeda) and olpasiran (licensed to Amgen). As an RNAi-based therapeutic targeting ANGPTL3, investigational zodasiran has the potential to treat HoFH in a fundamentally different manner from traditional LDL-C–lowering therapies. Share 'Patients living with HoFH are difficult to adequately treat and have a very high risk of developing atherosclerotic cardiovascular disease due to severely elevated LDL-C, often exceeding 500 mg/dL. As an RNAi-based therapeutic targeting ANGPTL3, investigational zodasiran has the potential to treat HoFH in a fundamentally different manner from traditional LDL-C–lowering therapies,' said James Hamilton, M.D., Chief Medical Officer and head of R&D at Arrowhead. 'In Phase 2 clinical studies, patients with HoFH receiving zodasiran achieved reductions from baseline in LDL-C, ApoB, non-HDL-C, and triglycerides, supporting its potential therapeutic role for the treatment of HoFH patients.' About Homozygous Familial Hypercholesterolemia Homozygous Familial Hypercholesterolemia (HoFH) is an ultra-rare treatment‐resistant genetic condition characterized by elevated low density lipoprotein cholesterol (LDL-C) and early-onset cardiovascular disease. Most cases of HoFH are due to mutations in the low-density lipoprotein receptor gene (LDLR) coding for the LDL receptor (LDLR). Thus, HoFH represents a unique case where LDL-C lowering therapies not requiring functional LDL receptors may have benefit. If left untreated, individuals with HoFH can have median LDL-C levels above 500 mg/dL (13 mmol/L), leading to early clinical manifestations of coronary artery disease 1. Patients with HoFH may also have cholesterol deposits under the skin (xanthomas), around the eyes (xanthelasmas), or around the cornea (corneal arcus), but physical signs are not always present, particularly in children. HoFH remains challenging to treat and currently only patients with the more severe HoFH phenotypes get diagnosed and treated early. The estimated prevalence of HoFH globally is between 1:360,000 and 1:250,000 1. About YOSEMITE Phase 3 Study YOSEMITE (NCT07037771) is a Phase 3 multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of zodasiran in adolescent and adult patients with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) on maximally tolerated lipid lowering therapy. Approximately 60 subjects over the age of 12 will be randomized (2:1) to receive 4 doses (once every 3 months) of 200 mg zodasiran or placebo. The primary endpoint is the percent change from baseline to month 12 in fasting LDL-C. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension. About Zodasiran Zodasiran, previously called ARO-ANG3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of angiopoietin-like protein (ANGPTL3), which is a hepatocyte expressed regulator of lipid and lipoprotein metabolism with multiple potential modes of action, including inhibition of lipoprotein lipase (LPL) and endothelial lipase (EL) 5,6. ANGPTL3 is an emerging therapeutic target with relevance to hypercholesterolemia, hypertriglyceridemia, and mixed hyperlipidemia. Genetic studies suggest that individuals with ANGPTL3 loss-of-function variants have enhanced lipoprotein lipase and endothelial lipase activity, resulting in lower levels of atherogenic lipoproteins and a reduced risk of ASCVD 2-4. In prior clinical studies, investigational zodasiran was associated with dose-dependent reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C, in patients with homozygous (HoFH) and heterozygous (HeFH) familial hypercholesterolemia and mixed hyperlipidemia. Zodasiran also showed a favorable safety profile. In the Phase 2 GATEWAY study in patients with HoFH, there were no drug discontinuations, drug-related serious adverse events, or deaths. The most frequent adverse events were COVID-19, nasopharyngitis, upper respiratory tract infection, and dizziness. About Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'may,' 'might,' 'will,' 'expect,' 'believe,' 'anticipate,' 'goal,' 'endeavor,' 'strive,' 'hope,' 'intend,' 'plan,' 'project,' 'could,' 'estimate,' 'potential,' 'target,' 'forecast' or 'continue' or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding regulatory approval for and commercial launch of plozasiran; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. ________________ 1. Cuchel, et al. Eur Heart J. 2023;44(25):2277-91 2. Dewey, et al. N Engl J Med. 2017;377 (3):211-21. 3. Minicocci, et al. J Lipid Res. 2013;54(12): 3481-90 4. Musunuru, et al. N Engl J Med. 2010; 363(23):2220-7 5. Adam, et al. J Lipid Res. 2020;61(9): 1271-86. 6. Rosenson. J Lipid Res. 2021:62:100060.
Time of India
08-07-2025
- Entertainment
- Time of India
Taylor Swift set to become Chiefs' biggest fan as she commits to Travis Kelce's full 2025 season
Taylor Swift is attending numerous Kansas City Chiefs games this NFL season (Getty Images) For the first time since she and Travis Kelce began dating, Taylor Swift is entering an NFL season without the crushing demands of a global tour. With her record-breaking Eras Tour officially wrapped, Swift is prioritizing time with her boyfriend — and that means a front-row seat to the Kansas City Chiefs' 2025 campaign. Taylor Swift clears her fall schedule to fully embrace Chiefs Kingdom alongside Travis Kelce According to a PEOPLE insider, 'Taylor plans to be at as many of his games as possible,' signaling a shift from a relationship long shaped by flight itineraries and tour stops to one rooted in routine, support, and shared Sundays. Swift wrapped up her 149-show, five-continent Eras Tour in December 2024 — an undertaking so massive it often meant red-eye flights between shows and stadium seats, trying to steal moments with Kelce between NFL road trips and post-show decompression. But now, with no performances standing in the way, the Grammy winner is reportedly 'really looking forward to the upcoming NFL season.' As the source emphasized, 'It's the first season where she's not constantly flying back and forth or working around an entire touring calendar.' The couple's early relationship played out under a cloud of chaos — Swift was on the move constantly, and Kelce was juggling football, fame, and family. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: One simple trick to get internet without a subscription Techno Mag Learn More Undo 'The past two seasons were a whirlwind between performing across multiple countries, long flights, and trying to squeeze in alone time together wherever possible,' the insider added. 'It wasn't easy but they made it work.' Kelce, for his part, never took her efforts for granted. 'She tried to get to as many as she could last year, and she came to a lot,' he said during an appearance on Bussin' with the Boys. 'We'll have Tay representing up at Arrowhead.' Now, as Kelce gears up for his 13th NFL season, the couple is embracing a new rhythm — one built around Sunday tailgates and fewer red carpets. Swift won't just be a rare face at the Super Bowl or high-profile matchups — she's expected to be a consistent presence in Arrowhead's suites and even at select away games. Also Read: Travis Kelce drops unexpected clues about building a future with Taylor Swift—and a secret new family member Their high-profile relationship has blurred the lines between the NFL and pop culture. But this fall, it's not about spectacle — it's about showing up. For Swift, that stage just happens to have end zones. Game On Season 1 continues with Mirabai Chanu's inspiring story. Watch Episode 2 here.
